- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06039254
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
September 14, 2023 updated by: Shandong Suncadia Medicine Co., Ltd.
A Multicenter, Non-randomized, Open-label, Parallel-controlled Study to Evaluate the Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
This is a multicenter, non-randomized, open-label, parallel-controlled study.
The main objective is to evaluate the safety and pharmacokinetics of HRS-1780 in subjects with mild and moderate renal impairment versus healthy subjects, and to provide a basis for dose selection of HRS-1780 in patients with chronic kidney disease.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yue Fei
- Phone Number: 0518-82342973
- Email: yue.fei@hengrui.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy subjects:
- Able to understand the trial procedures and possible risks, volunteers to participate in the trial, willing and able to comply with all scheduled visits and study procedures, and provides written informed consent.;
- Male and female, 18 to 70 years of age, inclusive;
- Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive;
- Normal glomerular filtration rate;
- No clinically significant abnormalities in physical examination, vital signs, laboratory tests, 12-lead ECG, etc. at the investigator's discretion;
- Men and WOCBP must agree to take highly effective contraceptive methods detailed in the protocol, have no plan to have a child from signing the consent form until at least one month after IP administration, and must not undertake for sperm/egg donation. Female participants should not be lactating.
Renal impairment subjects:
- Able to understand the trial procedures and possible risks, volunteers to participate in the trial, willing and able to comply with all scheduled visits and study procedures, and provides written informed consent.;
- Male and female, 18 to 70 years of age, inclusive;
- Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive;
- Glomerular filtration rate between 30 to 89 mL/min, inclusive;
- Except for renal impairment and related complications, no clinically significant abnormalities in physical examination, vital signs, laboratory tests, 12-lead ECG, etc. at the investigator's discretion;
- Men and WOCBP must agree to take highly effective contraceptive methods detailed in the protocol, have no plan to have a child from signing the consent form until at least one month after IP administration, and must not undertake for sperm/egg donation. Female participants should not be lactating.
Exclusion Criteria:
- Healthy subjects:
- Known history or suspected of being allergic to study drug or any component of it, or significant allergic reactions to other biologic products and drugs, or severe food allergies;
- Clinically significant abnormalities in 12-Lead ECG;
- Severe infections, injuries, or major surgeries as determined by the investigator within 3 months prior to screening, or plans to have surgeries during the study;
- Receipt of medical devices or another investigational drug (including placebo) within 3 months or 5 half-lives, whichever is longer prior to screening, or plans to participate in another clinical study during this study;
- Use of any prescription medicine, over-the-counter medicine, herbal remedy, or nutritional supplement within 2 weeks prior to screening;
- Consumption of more than 14 units of alcohol per week within 6 months prior to screening, or incapable to refrain from consuming alcohol during the study, or positive alcohol breath test result;
- Consumption of more than 5 cigarettes daily (or products with an equivalent amount of nicotine) within 3 months prior to screening, or use of any tobacco products 48 hours prior to dosing;
- History of illicit or prescription drug abuse or addiction in the past 5 years, or illicit or prescription drug abuse within 3 months prior to screening, or positive urine drug screen;
- Unwilling or unable to comply with the contraceptive methods detailed in this protocol;
- Positive hepatitis B virus, hepatitis B core antibody, hepatitis C virus, human immunodeficiency virus, or syphilis at screening;
- History or evidence of clinically significant disorders and deemed not suitable to participate in the study by the investigator within 6 months prior to screening;
- Inability to tolerate venipuncture blood collection;
- Any other circumstances that, in the investigator's judgment, may increase the risk to the subject, or associated with the subject's participation in and completion of the study.
Renal impairment subjects:
- History of kidney transplant or plan to receive a kidney transplant during the trial;
- Known history or suspected of being allergic to study drug or any component of it, or significant allergic reactions to other biologic products and drugs, or severe food allergies;
- Clinically significant abnormalities in 12-Lead ECG;
- Severe infections, injuries, or major surgeries as determined by the investigator within 3 months prior to screening, or plans to have surgeries during the study;
- Receipt of medical devices or another investigational drug (including placebo) within 3 months or 5 half-lives, whichever is longer prior to screening, or plans to participate in another clinical study during this study;
- Except for treatment of renal impairment and related complications, use of other prescription medicine, over-the-counter medicine, herbal remedy, or nutritional supplement within 2 weeks prior to screening;
- Consumption of more than 14 units of alcohol per week within 6 months prior to screening, or incapable to refrain from consuming alcohol during the study, or positive alcohol breath test result;
- Consumption of more than 5 cigarettes daily (or products with an equivalent amount of nicotine) within 3 months prior to screening, or use of any tobacco products 48 hours prior to dosing;
- History of illicit or prescription drug abuse or addiction in the past 5 years, or illicit or prescription drug abuse within 3 months prior to screening, or positive urine drug screen;
- Unwilling or unable to comply with the contraceptive methods detailed in this protocol;
- Positive hepatitis B virus, hepatitis B core antibody, hepatitis C virus, human immunodeficiency virus, or syphilis at screening;
- History or evidence of clinically significant disorders and deemed not suitable to participate in the study by the investigator within 6 months prior to screening;
- Inability to tolerate venipuncture blood collection;
- Any other circumstances that, in the investigator's judgment, may increase the risk to the subject, or associated with the subject's participation in and completion of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy subjects group
|
Single dose in each arm
|
Experimental: Mild renal impairment group
|
Single dose in each arm
|
Experimental: Moderate renal impairment group
|
Single dose in each arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics-Cmax
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Maximum observed concentration of HRS-1780
|
Start of Treatment to end of study (approximately 1 week)
|
Pharmacokinetics-AUC0-last
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Area under the concentration-time curve from time 0 to last time point after HRS-1780 administration
|
Start of Treatment to end of study (approximately 1 week)
|
Pharmacokinetics-AUC0-inf
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Area under the concentration-time curve from time 0 to infinity after HRS-1780 administration
|
Start of Treatment to end of study (approximately 1 week)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics-Tmax
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Time to Cmax of HRS-1780
|
Start of Treatment to end of study (approximately 1 week)
|
Pharmacokinetics-t1/2
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Terminal elimination half-life of HRS-1780
|
Start of Treatment to end of study (approximately 1 week)
|
Pharmacokinetics-CL/F
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Apparent clearance of HRS-1780
|
Start of Treatment to end of study (approximately 1 week)
|
Pharmacokinetics-Vz/F
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Apparent volume of distribution during terminal phase of HRS-1780
|
Start of Treatment to end of study (approximately 1 week)
|
Pharmacokinetics-Cumulative excretion (Ae)
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Cumulative amount of HRS-1780 excreted in urine
|
Start of Treatment to end of study (approximately 1 week)
|
Pharmacokinetics-Cumulative excretion rate (Ae%)
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Cumulative percentage of HRS-1780 recovered in urine
|
Start of Treatment to end of study (approximately 1 week)
|
Pharmacokinetics-Renal clearance (CLr)
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Clearance of HRS-1780 by kidney
|
Start of Treatment to end of study (approximately 1 week)
|
Binding rates of plasma protein (BRPP) of HRS-1780
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Binding rates of plasma protein
|
Start of Treatment to end of study (approximately 1 week)
|
Adverse events
Time Frame: Start of Treatment to end of study (approximately 1 week)
|
Incidence and severity of adverse events
|
Start of Treatment to end of study (approximately 1 week)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2023
Primary Completion (Estimated)
November 30, 2023
Study Completion (Estimated)
December 8, 2023
Study Registration Dates
First Submitted
August 7, 2023
First Submitted That Met QC Criteria
September 14, 2023
First Posted (Actual)
September 15, 2023
Study Record Updates
Last Update Posted (Actual)
September 15, 2023
Last Update Submitted That Met QC Criteria
September 14, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRS-1780-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on HRS-1780
-
Shandong Suncadia Medicine Co., Ltd.Active, not recruitingChronic Kidney DiseaseChina
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruitingAdvanced Malignant Tumour
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Guangdong Hengrui Pharmaceutical Co., LtdEnrolling by invitationRefractory Chronic CoughChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Grupo Español de Rehabilitación MultimodalUnknownArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipSpain
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced KRAS G12D Mutant Solid TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting